Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Aptalis Pharmatech Inc.

AstraZeneca, Eli Lilly and Cancer Dominate 2016 EU New Drug Approvals

2016 saw 30 new active substances approved in the EU, in a total of 29 different products, of which 10 were for cancer indications. Two companies shared the honors for productivity: AstraZeneca and Lilly each saw three new active substances approved by the European Commission during the year.

Europe Approvals

Oncology Captures One In Three New EU Drug Approvals In 2016

2016 saw 30 new active substances approved in the EU, in a total of 29 different products, of which 10 were for cancer indications. Also approved were a range of combinations of old and new drugs, some new uses, and a number of biosimilars and generics. 14 of the products approved during the year were for rare diseases, while eight received a conditional marketing authorization.

Approvals BioPharmaceutical

Biopharma Quarterly Dealmaking Statistics, Q1 2015

Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.

BioPharmaceutical Deals

Life After White Oak: Hamburg’s Predecessors Offer Glimpse At Where Pharma Might See Her Again

In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Adare Pharmaceuticals
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aptalis Pharmatech Inc.
  • Senior Management
  • John Fraher, Pres. & CEO
    Joseph Del Buono, VP, Fin. & CFO
  • Contact Info
  • Aptalis Pharmatech Inc.
    Phone: (937) 415-0330
    845 Center Dr.
    Vandalia, OH 45377-3129
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register